---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Expanded access program in Tumor hyperinsulinism"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Expanded access program in Tumor hyperinsulinism. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 83 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence/expanded-access-program-in-tumor-hyperinsulinism"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Expanded access program in Tumor hyperinsulinism

<a id="heading-3.1.2"></a>

## 3.1.2 Expanded Access Program in Tumor Hyperinsulinism

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Objective of the peer-reviewed case series: insulinoma and cervical neuroendocrine carcinoma

> “We retrospectively report outcomes from compassionate use of ersodetug in 8 individuals with refractory hypoglycemia due to tumor HI.”
> “this case series retrospectively reports on the experience of 8 individuals with refractory hypoglycemia due to tumor HI (metastatic insulin-producing tumors) who were treated with ersodetug on a compassionate use basis via an expanded access program (EAP).”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.1-2"></a>

#### Purpose of the expanded access program

> “The EAP was initiated to provide compassionate access to ersodetug for individuals with severe, refractory hypoglycemia due to HI.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

> “for a variety of HI indications for the purpose of making ersodetug available on a compassionate use basis when patients have refractory hypoglycemia and cannot access a clinical trial.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-3.1.2.1-3"></a>

#### Objective of the ENDO 2026 case series poster

> “We examined the real-world outcomes from a case-series of patients with refractory hypoglycemia due to metastatic insulin-producing neuroendocrine tumors who received ersodetug for compassionate use as part of an EAP”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-3.1.2.1-4"></a>

#### Objective of the NANETS 2024 poster

> “To report the case experiences from a cohort of patients who have received RZ358 to treat tumorHI.”

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-3.1.2.1-5"></a>

#### Objective of the single published case: metastatic insulinoma

> “We report the successful use of RZ358, a novel human anti–insulin receptor monoclonal antibody, in a patient with metastatic insulinoma in whom severe, refractory hypoglycemia developed after peptide receptor radionuclide therapy with lutetium Lu 177 dotatate.”

Source: [Osataphan et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10506502/)

<a id="topic-3.1.2.1-6"></a>

#### Purpose of the intermediate-size cohort expanded access program: insulinoma and NICTH

> “This expanded access program is intended to provide ersodetug, an investigational drug, to eligible participants who suffer from inadequately controlled hypoglycemia due to tumor-associated hyperinsulinism and are unable to participate in ersodetug clinical trial.”

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Enrollment period, data cutoff, and countries in the peer-reviewed case series

> “Eight individuals with refractory hypoglycemia secondary to HI whose glycemic needs were not adequately managed by standard-of-care therapies were enrolled in the EAP beginning in November 2022; data were collected until the data cutoff of August 2025.”
> “were enrolled in the EAP in the United States (n = 7) and the Netherlands (n = 1)”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.2-2"></a>

#### First patient treated at a single U.S. center under FDA emergency use authorization

> “We obtained emergency use authorization from the Food and Drug Administration, approval from the institutional review board of Beth Israel Deaconess Medical Center, and written informed consent from the patient.”

Source: [Osataphan et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10506502/)

<a id="topic-3.1.2.2-3"></a>

#### Investigators in the United States and Europe, as stated by the company in January 2026

> “Over the past two years, Rezolute has collaborated with investigators across the United States and in Europe to provide ersodetug to more than a dozen patients with severe and refractory hypoglycemia due to tumor HI, including malignant pancreatic neuroendocrine tumors (insulinomas) and non-islet cell tumors.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.2.2-4"></a>

#### Status, dates, and location of the intermediate-size cohort expanded access program

| Field | Quoted record |
| --- | --- |
| Expanded access status | “Available” |
| Other study ID number | “RZ358-303” |
| First submitted | “2025-11-21” |
| First posted | “2025-12-04” |
| Last update posted | “2026-10-07” |
| Location | “New Orleans, Louisiana, United States, 70112” |

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="topic-3.1.2.2-5"></a>

#### Program continuing after completion of upLIFT enrollment

> “The Company plans to continue its expanded access program for purposes of providing ersodetug on a compassionate use basis to individuals living with serious and refractory hypoglycemia due to tumor HI.”

Source: [Rezolute upLIFT enrollment completion release (2026)](https://ir.rezolutebio.com/news/detail/386/rezolute-announces-completion-of-enrollment-in-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Retrospective case series of single-patient compassionate use requests

> “Enrollment was initiated by a treating physician through a named patient request (single-patient investigational new drug application) to the country health authority and was approved by local institutional review board, if required.”
> “Written informed consent was obtained from all individuals before treatment initiation.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.3-2"></a>

#### Change from an earlier compassionate use framework to a tumor HI-specific framework

> “The first 2 individuals were enrolled under an earlier compassionate-use program framework; a subsequent, tumor HI–specific framework was implemented during the course of the third patient's treatment and applied to all remaining individuals.”
> “The updated framework incorporated a higher weekly dose that had shown superior effectiveness in early experience”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.3-3"></a>

#### Overlap of the first patient with the published single case

> “For Patient 1, the continuous glucose monitoring (CGM) and glucose infusion rate (GIR) data for the 90-day pre- and post-treatment windows presented herein also were previously reported in a single case report”
> “all other efficacy data for this patient are new.”
> “This patient was the first to receive ersodetug for tumor HI, with detailed results previously reported in a case report”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.3-4"></a>

#### Role of the expanded access data in Breakthrough Therapy Designation and the upLIFT redesign

> “This same data cohort was provided to FDA last year in support of the Company’s request for Breakthrough Therapy Designation and subsequently informed the discussion with FDA that led to revision of the Phase 3 upLIFT study in tumor HI to a single arm, open-label study.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

> “is substantially based upon the favorable outcomes that we have observed over the last two years treating more than 10 patients with tumor HI under our Expanded Access Program.”

Source: [Rezolute upLIFT design alignment release (2025)](https://ir.rezolutebio.com/news/detail/361/rezolute-announces-alignment-with-fda-on-streamlined-design-for-ongoing-phase-3-trial-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-3.1.2.3-5"></a>

#### Design of the intermediate-size cohort expanded access program

| Field | Quoted record |
| --- | --- |
| Official title | “Intermediate-Size Cohort EAP for Ersodetug in Patients With Refractory Hypoglycemia Due to Tumor-Associated Hyperinsulinism (Tumor HI) Who Are Unable to Participate in a Clinical Trial” |
| Study type | “Expanded Access” |
| Expanded access type | “Intermediate-size Population” |
| Condition | “Tumor-associated Hyperinsulinism (Tumor HI)” |
| Sponsor | “Rezolute” |

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Eligibility in the peer-reviewed case series

> “Individuals were eligible regardless of tumor type, prior therapies, or comorbidities, provided they were clinically stable for infusion.”
> “All listed diagnoses were confirmed by relevant laboratory, imaging and pathology over the treatment courses and prior to initiating ersodetug.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.4-2"></a>

#### Inclusion criteria of the intermediate-size cohort expanded access program: insulinoma and NICTH

> “Uncontrolled hypoglycemia due to documented tumor HI (including but not limited to: insulin/pro-insulin producing pancreatic/non-pancreatic neuroendocrine tumors, insulin-like growth factor-producing NICTH) that is not adequately managed with available SoC anti-hypoglycemic therapies (per Treating Physician's judgement).”
> “Inability to participate in any ersodetug clinical trial.”
> “Women of childbearing potential (WOCBP) must not be pregnant or breast feeding, and must be willing to use effective contraceptive measures or practice complete sexual abstinence to prevent pregnancy for the duration of the Cohort EAP AND for at least 5 months after receiving the last dose of ersodetug.”

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="topic-3.1.2.4-3"></a>

#### Exclusion criteria of the intermediate-size cohort expanded access program

> “Evidence of active infection including (but not limited to) human immunodeficiency virus, hepatitis B, or hepatitis C.”
> “Known allergy or sensitivity to ersodetug or any component of the drug.”
> “Treatment with an investigational drug or device within 30 days or 5 t½ of the investigational drug before the planned 1st dose of ersodetug, whichever is longer.”

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="topic-3.1.2.4-4"></a>

#### Age and sex eligibility of the intermediate-size cohort expanded access program

| Field | Quoted record |
| --- | --- |
| Ages eligible | “18 Years and older” |
| Sexes eligible | “All” |

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Dose, route, and schedule in the peer-reviewed case series

> “Ersodetug was administered intravenously over 30 minutes at an initial dose of 6 or 9 mg/kg, given either weekly or every other week initially, followed by a frequency of every 2-5 weeks, as appropriate, at the discretion of the treating physician.”
> “Dose adjustments, including titration and changes in dosing frequency, were made based on glycemic response, tolerability, and clinical course.”
> “After exploratory dose-ranging in the first 2 participants, the initiation dose regimen was standardized in subsequent participants to 9 mg/kg weekly, followed by de-escalation as indicated.”
> “One participant required escalation from 9 to 12 mg/kg every other week.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.5-2"></a>

#### Concomitant standard-of-care and tumor-directed therapy

> “Supportive therapies, including use of ongoing standard-of-care antihypoglycemic treatments, were noted and recorded.”
> “Individuals resumed tumor-directed therapies or procedures as deemed appropriate by the multidisciplinary clinical care team, and these interventions were systematically recorded as part of the observational dataset.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.5-3"></a>

#### Drug supplied at no cost by the manufacturer

> “Rezolute, Inc. (Redwood City, CA, USA) provided ersodetug at no cost to participating institutions for use under health authority–authorized compassionate use programs.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.5-4"></a>

#### Dose regimen by patient in the company table of 9 patients

| Patient | Ersodetug dose regimen (dose/frequency) |
| --- | --- |
| Patient 1 | “6-9 mg/kg every 1-4 weeks” |
| Patient 2 | “6-9 mg/kg every 1-2 weeks” |
| Patient 3 | “9 mg/kg, every 1-2 weeks” |
| Patient 4 | “9-12 mg/kg every 1-2 weeks” |
| Patient 5 | “9 mg/kg every 1-3 weeks” |
| Patient 6 | “9 mg/kg every 1-2 weeks” |
| Patient 7 | “6-9 mg/kg every 1-2 weeks” |
| Patient 8 | “9 mg/kg every 1-2 weeks” |
| Patient 9 | “9 mg/kg every 1-3 weeks” |

Source: [Rezolute EAP patient profiles (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-2.htm)

<a id="topic-3.1.2.5-5"></a>

#### Dosing in the ENDO 2026 case series poster

> “All patients received ersodetug in open-label fashion at doses of 6 or 9 mg/kg every 1-2 weeks initially, followed by a frequency of every 2-4 weeks as tolerated, as add on to standard of care (e.g. diazoxide, somatostatin analogues, etc.), which could be weaned as appropriate”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-3.1.2.5-6"></a>

#### Dosing in the NANETS 2024 poster

> “Ersodetug was initiated at 6 or 9mg/kg every 1-2 weeks (by 30-min intravenous infusion), and titrated to response, at physician discretion.”

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-3.1.2.5-7"></a>

#### Dosing range stated by the company

> “Generally, dosing for tumor HI patients in the EAP has been either 6 mg/kg or 9 mg/kg every 1-4 weeks.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-3.1.2.5-8"></a>

#### Intervention in the intermediate-size cohort expanded access program

| Field | Quoted record |
| --- | --- |
| Intervention | “Drug: Ersodetug (9 mg/kg) + SOC” |
| Description | “Open-Label Participants with a diagnosis of Tumor HI (insulin- or IGF-producing tumors)” |

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Discontinuation of Parenteral Glucose as the Primary Outcome

<a id="topic-3.1.2.6.1-1"></a>

##### No prespecified primary outcome: efficacy assessments centered on glucose infusion rate

> “Assessments of efficacy focused on changes in GIR (since most participants initially required parenteral dextrose to correct refractory hypoglycemia) and also included assessments of hypoglycemia by CGM (described below), number of hospitalization days in the month before and after ersodetug initiation, and overall survival.”
> “Eastern Cooperative Oncology Group (ECOG) performance status was used to assess functional ability.”
> “The ersodetug dosing regimen, treatment duration, and safety observations (serious adverse events and drug-related serious adverse events) were also recorded and assessed.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.6.1-2"></a>

##### Parenteral dextrose at baseline masks hypoglycemia measured by continuous glucose monitoring

> “Most individuals were receiving parenteral dextrose during baseline, which by intent likely ameliorated hypoglycemia, thus masking the severity of baseline glycemic measures by CGM.”
> “Therefore, changes from baseline in CGM should be interpreted accordingly.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.6.1-3"></a>

##### Continuous glucose monitoring outcomes and windows

> “CGM data were analyzed for mean sensor glucose and percent of time in predefined glycemic ranges (eg, <70 mg/dL, <54 mg/dL, and >180 mg/dL).”
> “Baseline for CGM purposes was defined as the period up to 90 days before the first dose of ersodetug, and the evaluable window was defined as the period up to 90 days after initiation; longer follow-up CGM data were included in a sensitivity analysis.”
> “Its pharmacokinetic characteristics informed selection of a 90-day evaluable window during which drug concentrations were expected to be at steady-state for most individuals.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.6.1-4"></a>

##### Parenteral infusion as a barrier to discharge and to tumor-directed therapy

> “Supportive strategies such as frequent carbohydrate intake or continuous parenteral dextrose infusion are often required but are burdensome and do not provide durable control, and parenteral infusions may prevent hospital discharge.”
> “These functional gains enabled most individuals to pursue tumor-directed therapies, including chemotherapy, surgery, and hepatic arterial embolization, underscoring the importance of glycemic stabilization as a prerequisite for oncologic care in this population.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.6.1-5"></a>

##### Glucose infusion rate as the focus of the ENDO 2026 case series analysis

> “Glycemic and safety outcomes were reported and analyzed descriptively with a focus on the change from baseline in the GIR as a function of hypoglycemia”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-3.1.2.6.1-6"></a>

##### Glucose infusion rate assessment shared with the upLIFT primary endpoint

> “Notably, the GIR assessment in the EAP is the primary endpoint in upLIFT, which measures the number of participants (out of ~16) who achieve at least a 50% reduction in GIR, an objective endpoint in a highly controlled hospital setting.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Peer-reviewed case series: 8 participants

> “Eight adults (4M/4F; 24-74 years; Eastern Cooperative Oncology Group [ECOG] 1-3) received ersodetug for insulin-secreting tumors (metastatic insulinoma, n = 7; cervical neuroendocrine carcinoma, n = 1).”
> “All 8 individuals had CGM data available.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.7.1-2"></a>

##### ENDO 2026 poster: 9 patients

> “As of the data cut, 9 patients with refractory hypoglycemia due to malignant insulinoma had received ersodetug and are included in this retrospective case series report”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-3.1.2.7.1-3"></a>

##### Company table filed with the SEC: 9 patients

> “Presented in a table filed today on Form 8-K with the U.S. Securities and Exchange Commission are cumulative data from the initial 9 participants in the EAP, including patient characteristics, ersodetug dosing, and observed outcomes.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.2.7.1-4"></a>

##### ENDO 2026 company release: 9 patients with malignant insulinoma and non-islet cell tumors

> “A third poster presentation highlighted favorable outcomes from a case series report of 9 patients with refractory hypoglycemia due to malignant insulinoma and non-islet cell tumors (tumor HI), demonstrating that 75% of the patients receiving IV dextrose/total parenteral nutrition (TPN) in the EAP achieved a complete discontinuation of IV dextrose/TPN.”

Source: [Rezolute ENDO presentations release (2026)](https://ir.rezolutebio.com/news/detail/380/rezolute-highlights-results-presented-from-natural-history-outcomes-studies-and-its-ersodetug-clinical-program-in-hyperinsulinism-at-annual-meeting-of-the-endocrine-society)

<a id="topic-3.1.2.7.1-5"></a>

##### NANETS 2024 poster: 5 patients

> “Five adult patients (2M/3F) with refractory hypoglycemia due to metastatic insulin producing tumors received treatment with ersodetug after FDA/IRB-approval.”

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-3.1.2.7.1-6"></a>

##### Total patients treated under the program, as stated by the company: more than 10 to 13

> “More than 10 tumor HI patients to date have successfully been treated in the Expanded Access Program.”

Source: [Rezolute congenital HI breakthrough therapy release (2025)](https://ir.rezolutebio.com/news/detail/345/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-congenital-hyperinsulinism)

> “13 patients with tumor HI treated in our Expanded Access Program (EAP) to date”

Source: [Rezolute investor event presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm)

> “To date, we have received numerous inbound physician inquiries regarding the use of ersodetug in patients with tumor HI caused by metastatic insulinomas or non-islet cell tumors, which led to compassionate use treatment in an expanded access program in more than a dozen patients.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Analysis population and evaluation periods in the peer-reviewed case series

> “In this retrospective analysis, observational data were collected until August 2025 (or earlier treatment discontinuation) in all individuals who received at least one infusion of ersodetug and had available follow-up data.”
> “For standardization of glycemic assessments, baseline was defined as the period up to 90 days prior to ersodetug initiation.”
> “The evaluable period was defined as the time from ersodetug initiation until the data cutoff (August 2025) or treatment discontinuation.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.7.2-2"></a>

##### Parenteral glucose subset: 7 of 8 participants

> “Of the 7 individuals who were receiving parenteral glucose, including one on home TPN, baseline GIRs at ersodetug initiation ranged from 3.1 to 7.0 mg/kg/min.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

> “Seven of the 8 patients receiving parenteral glucose at baseline achieved at least a 50% reduction”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-3.1.2.7.2-3"></a>

##### Paired nonparametric comparisons without formal hypothesis testing

> “Changes in percent time in glycemic ranges and medication counts were assessed from paired comparisons of the baseline period (up to 90 days) with the post-initiation evaluable period (up to 90 days) using the Wilcoxon-signed rank test in R.”
> “95% intervals could not be constructed due to the sample size [N = 8] and discrete nature of the test”
> “Strength of statistical evidence was evaluated using nominal P-values, but no formal or prespecified hypothesis testing was conducted due to the retrospective nature of the report and limited sample size.”
> “A statistical analysis plan with additional details of the statistical methods was developed after primary data analyses and is available in the Supplemental Appendix”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Treatment duration, dosing de-escalation, and deaths in the peer-reviewed case series

> “Most individuals (n = 6/8) were able to decrease the dosing frequency of ersodetug after hospital discharge.”
> “The median treatment duration with ersodetug of 11.5 months (range 5-17 months; ongoing in 2 individuals) also corresponded to patient lifespan and overall survival in the setting of metastatic disease.”
> “Of the individuals who died (n = 6), tumor progression and sepsis were cited as the cause, unrelated to the investigational drug.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.1-2"></a>

##### Treatment duration and survival by patient in the company table of 9 patients

| Patient | Total duration of ersodetug therapy (months) | Overall survival (months) |
| --- | --- | --- |
| Patient 1 | “13” | “14” |
| Patient 2 | “5” | “5” |
| Patient 3 | “5” | “5” |
| Patient 4 | “14” | “14” |
| Patient 5 | “22 (ongoing)” | “22 (living)” |
| Patient 6 | “18 (ongoing)” | “18 (living)” |
| Patient 7 | “6” | “6” |
| Patient 8 | “1.5” | “1.5” |
| Patient 9 | “10” | “10” |

Source: [Rezolute EAP patient profiles (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-2.htm)

<a id="topic-3.1.2.8.1-3"></a>

##### Critically ill patient who died of sepsis before response could be assessed: company table

> “Patient was critically ill when treatment commenced and died of sepsis prior to determination of whether there was a therapeutic effect”

Source: [Rezolute EAP patient profiles (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-2.htm)

<a id="topic-3.1.2.8.1-4"></a>

##### First two patients still receiving treatment in October 2023

> “The patient began receiving treatment with RZ358 in September 2023”
> “Notably, the individual with metastatic insulinoma has remained on RZ358 for nearly a year.”

Source: [Rezolute tumor HI evidence release (2023)](https://ir.rezolutebio.com/news/detail/318/rezolute-announces-further-evidence-of-rz358s-efficacy-in-tumor-mediated-hyperinsulinism)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Demographics and clinical characteristics in the peer-reviewed case series

> “All individuals were White; 7 identified as non-Hispanic and one as Hispanic.”
> “Seven individuals had metastatic insulinoma and one had neuroendocrine carcinoma of the cervix.”
> “The cohort was characterized by predominantly metastatic disease with substantial hepatic involvement and variable but often abnormal liver biochemistry, along with renal function ranging from normal to mildly impaired at the time of ersodetug initiation.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.2-2"></a>

##### Hospitalization at entry stated in the text of the peer-reviewed case series

> “Six of the 8 individuals were hospitalized at EAP entry (median, 28 days; range, 4-66 days), largely due to glycemic instability and the need for inpatient or intensive parenteral glucose support.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.2-3"></a>

##### Prior therapy, home parenteral nutrition, performance status, and hospice consideration at entry

> “All individuals had received and were refractory to at least 3 standard-of-care therapies, including diazoxide, short- and long-acting somatostatin analogs, everolimus, and/or corticosteroids.”
> “Two individuals initiated ersodetug prior to hospitalization, including one receiving continuous carbohydrate supplementation via home TPN.”
> “Four of the 8 individuals had a baseline ECOG score of 3, 1 had an ECOG of 2, and 3 had an ECOG of 1.”
> “Two individuals were under hospice consideration at baseline due to refractory hypoglycemia, progressive disease, and lack of remaining tumor-directed treatment options.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.2-4"></a>

##### Demographics, tumor, and organ function by patient in the peer-reviewed case series

| Characteristic | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Gender; age (years) | “M; 55” | “F; 50” | “F; 50” | “F; 43” | “M; 74” | “M; 62” | “F; 74” | “M; 24” |
| Country | “U.S.” | “U.S.” | “U.S.” | “U.S.” | “U.S.” | “U.S.” | “U.S.” | “The Netherlands” |
| Race/ethnicity | “White, Hispanic” | “White, Non-Hispanic” | “White, Non-Hispanic” | “White, Non-Hispanic” | “White, Non-Hispanic” | “White, Non-Hispanic” | “White, Non-Hispanic” | “White, Non-Hispanic” |
| Diagnosis | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Neuroendocrine Carcinoma of the Cervix” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Insulinoma” |
| Diagnosis year | “2021” | “2015” | “2022” | “2021” | “2023” | “2019” | “2022” | “2022” |
| Tumor primary site | “Pancreas” | “Pancreas” | “Cervix (neuroendocrine carcinoma)” | “Pancreas” | “Pancreas (primary pancreatic NET with liver metastases)” | “Pancreas (well-differentiated pancreatic NET)” | “Pancreas (well-differentiated NET in pancreatic body)” | “Pancreas (primary insulinoma diagnosed 2022; right-sided hemihepatectomy in 2024 at time of insulinoma)” |
| Ki-67 (% and biopsy site) | “8% (liver metastasis biopsy)” | “17.6% (liver resection specimen); primary pancreatic tumor Ki-67 9%” | “75% (liver metastasis biopsy)” | “5% (pancreatic primary tumor)” | “35% (liver metastasis; secondary tumor)” | “Unknown (fine-needle aspiration showing well-differentiated pancreatic NET)” | “42% (liver core needle biopsy; WHO grade 3 well-differentiated NET)” | “16% (pancreatic primary); 17.8% (liver metastasis)” |
| Metastatic sites and burden | “Multiple abdominal and multilobar hepatic lesions, abdominal pain” | “Liver, gastrohepatic lymph nodes, osseous metastases” | “Extensive metastatic burden (Multilobar liver and pelvic metastases)” | “Extesive metastatic burden (Liver, lymph nodes, bone)” | “Extensive liver tumor burden” | “Liver, periportal lymph nodes, para-aortic lymph nodes, low overall disease burden” | “Extensive bilobar hepatic metastatic burden; left hilar metastasis” | “Extensive liver tumor burden, involving an estimated 33% of the remaining left hemi-liver” |
| Hepatic function at initiation | “Mild ↑ transaminases, low albumin” | “Marked ↑ transaminases, low albumin” | “Mild ↑ in alk phos, low albumin” | “Marked ↑ alk phos, low albumin” | “Mild ↑ alk phos, low albumin” | “Modest ↑ transaminases” | “Moderate ↑ alk phos” | “Mild ↑ transaminases, and alk phos” |
| ALT, AST (U/L) | “81, 38” | “148, 144” | “22. 17” | “20, 53” | “36, 26” | “87, 75” | “44, 20” | “40, 44” |
| Alkaline phosphatase (U/L) | “105” | “620” | “173” | “677” | “108” | “104” | “255” | “161” |
| Albumin (g/dL) | “3.4” | “3.1” | “3.4” | “3.1” | “3.1” | “3.9” | “3.8” | “3.8” |
| PT (sec) | “NA” | “16.9” | “18.4” | “12” | “11.3” | “11.5” | “13.9” | “NA” |
| INR (ratio) | “1.1” | “NA” | “NA” | “NA” | “1.0” | “1.0” | “1.2” | “1.1” |
| Renal function at initiation | “Normal” | “Normal” | “Impaired” | “Mildly impaired” | “Normal” | “Normal” | “Normal” | “Mildly impaired” |
| Creatinine (mg/dL) | “1.2” | “0.8” | “2.13” | “1.26” | “1.1” | “0.9” | “0.63” | “1.3” |
| eGFR (mL/min/1.73 m2) | “NA” | “90” | “49” | “54” | “>60” | “>60” | “93” | “73” |

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.2-5"></a>

##### Hospitalization, performance status, and prior antihypoglycemic therapy by patient in the peer-reviewed case series

| Characteristic | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Length of hospitalization before ersodetug (days) | “28” | “NA (ambulatory)” | “15” | “49” | “34” | “NA (ambulatory)” | “4” | “16” |
| Hospice planning before ersodetug | “Y” | “N” | “Y” | “N” | “N” | “N” | “N” | “N” |
| Baseline ECOG | “3” | “2” | “3” | “3” | “3” | “1” | “1” | “1” |
| Number of therapies for hypoglycemia (medications and IV glucose) before ersodetug | “4” | “6” | “4” | “5” | “4” | “2” | “3” | “2” |
| Diazoxide | “+” | “+” | “+” | “+” | “Previously Tried” | “Previously Tried” | “Previously Tried” | “+” |
| Short-acting somatostatin analog (octreotide or pasireotide) | “Previously Tried” | “+” | “+” | “Previously Tried” | “+” | “NA” | “Previously Tried” | “Previously Tried” |
| Long-acting somatostatin analog (lanreotide) | “−” | “+” | “NA” | “+” | “NA” | “+” | “Previously Tried” | “NA” |
| mTOR inhibitor (everolimus) | “+” | “+” | “NA” | “+” | “+” | “+” | “+” | “NA” |
| Corticosteroid (dexamethasone, prednisone) | “+” | “+” | “+” | “+” | “+” | “NA” | “+” | “NA” |
| GIR at ersodetug initiation (mg/kg/min) | “6.0” | “7.0” | “5.1” | “6.2” | “4.9” | “NA” | “5.6” | “3.1” |

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.2-6"></a>

##### Baseline characteristics by patient in the company table of 9 patients

| Characteristic | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Gender (M/F) / age (years) | “M / 55” | “F / 50” | “F / 50” | “F / 43” | “M / 74” | “M / 62” | “M / 74” | “M / 53” | “M / 24” |
| Diagnosis | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Neuroendocrine Carcinoma of the Cervix” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Insulinoma” | “Metastatic Proinsulinoma” | “Metastatic Insulinoma” |
| Number of antihypoglycemic therapies at enrollment | “4” | “3” | “3” | “4” | “4” | “3” | “5” | “2” | “4” |
| GIR at ersodetug initiation (mg/kg/min) | “6.0” | “7.0 (home TPN)” | “5.1” | “6.2” | “4.9” | “n/a (ambulatory)” | “5.6” | “Unknown amount” | “3.1” |
| Length of hospitalization before ersodetug (days) | “28” | “n/a (ambulatory)” | “15” | “49” | “34” | “n/a (ambulatory)” | “4” | “Unknown duration” | “16” |
| Baseline ECOG | “3” | “2” | “3” | “3” | “3” | “1” | “1” | “3” | “1” |

Source: [Rezolute EAP patient profiles (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-2.htm)

<a id="topic-3.1.2.8.2-7"></a>

##### Patients and tumor types in the NANETS 2024 poster

| Patient | Gender | Age | Tumor type |
| --- | --- | --- | --- |
| Patient 1 | “M” | “55” | “Metastatic Insulinoma” |
| Patient 2 | “F” | “50” | “Metastatic Insulinoma” |
| Patient 3 | “F” | “50” | “Metastatic Insulin-Secreting Tumor (Cervical Primary)” |
| Patient 4 | “F” | “43” | “Metastatic Insulinoma” |
| Patient 5 | “M” | “74” | “Metastatic Insulinoma” |

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-3.1.2.8.2-8"></a>

##### Parenteral dextrose and hospital setting at entry in the NANETS 2024 poster

> “At program entry, all patients required continuous parenteral dextrose, including 4 in a prolonged hospital setting.”

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-3.1.2.8.2-9"></a>

##### Single published case: presentation, tumor, and biochemistry

> “A 55-year-old man presented with a 5-month history of abdominal pain and weight loss.”
> “A liver biopsy revealed a pancreatic neuroendocrine tumor”
> “with a pathogenic MEN1 mutation.”
> “Hormonal analysis, performed when the venous glucose level was 41 mg per deciliter (2.3 mmol per liter), revealed inappropriately high levels of insulin, at 45 μIU per milliliter (312 pmol per liter; reference value, <19.6 μIU per milliliter [141 pmol per liter]); C-peptide, at 6.5 ng per milliliter (reference range, 0.80 to 3.85); and proinsulin, at 453 pmol per liter (reference value, <18).”

Source: [Osataphan et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10506502/)

<a id="topic-3.1.2.8.2-10"></a>

##### Single published case: refractory hypoglycemia on maximal therapy before ersodetug

> “Intravenous 50% dextrose solution was infused through a central line, at a rate of up to 60 ml (30 g) per hour, which reflects very high glucose use.”
> “Despite enteral nutrition support and treatment with high-dose diazoxide, everolimus, dexamethasone, pasireotide, and glucagon, the patient remained hypoglycemic, with up to 58% of all sensor glucose values in each 24-hour period being less than 70 mg per deciliter [3.9 mmol per liter] and up to 19% being less than 54 mg per deciliter (3.0 mmol per liter)”

Source: [Osataphan et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10506502/)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Summary of glycemic outcomes in the peer-reviewed case series

> “Most patients experienced improved glycemic control, including discontinuation of parenteral glucose in 6 of the 7 applicable patients (median, 4.5 days) and a 35.6% relative reduction from baseline in time in hypoglycemia (<70 mg/dL) by continuous glucose monitoring (mean 12.4-8.0%; pseudo-median paired change of -3.8 percentage points [90% CI, −8.2 to −1.1]; P = .02).”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-2"></a>

##### Discontinuation of parenteral glucose: 6 of 7 participants

> “Six of 7 individuals on parenteral glucose support at baseline discontinued it within the 90-day post-therapy window (median time, 4.5 days), which allowed for subsequent reductions in other standard-of-care antihypoglycemic therapies.”
> “One individual on home TPN initiated ersodetug contemporaneously with ablation of primary hepatic metastases, ultimately achieving a 50% reduction in intravenous carbohydrate support after dose escalation of ersodetug to 9 mg/kg biweekly.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-3"></a>

##### Number of antihypoglycemic therapies before and after initiation

> “The total number of therapies decreased from a mean of 3.8 to 1.6 during the 90 days after ersodetug initiation (median change, −2.5; 90% CI, −3.5 to −1.0; P = .02)”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-4"></a>

##### Time to discontinuation of each antihypoglycemic therapy by patient (days unless stated)

| Therapy | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| IV glucose | “74 (slow taper)” | “139 (50% reduction)” | “4” | “5” | “2” | “NA” | “3” | “42” |
| Diazoxide | “111” | “10” | “4” | “21” | “NA” | “NA” | “NA” | “Ongoing” |
| Short-acting somatostatin analog (octreotide or pasireotide) | “NA” | “18” | “4” | “NA” | “8” | “NA” | “NA” | “NA” |
| Long-acting somatostatin analog (lanreotide) | “NA” | “Ongoing” | “NA” | “30” | “NA” | “Ongoing” | “NA” | “NA” |
| mTOR inhibitor (everolimus) | “∼6 months” | “18” | “NA” | “Ongoing” | “8” | “Ongoing” | “Ongoing” | “NA” |
| Corticosteroid (dexamethasone, prednisone) | “∼7 months” | “∼4 months” | “4 days” | “Ongoing” | “NA” | “NA” | “Ongoing” | “NA” |

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-5"></a>

##### Hospital discharge, tumor-directed therapy, performance status, and survival by patient

| Outcome | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Time to discharge from hospital (days) | “84” | “NA” | “7” | “15” | “9” | “NA” | “9” | “1” |
| Hospitalization days in month after initiation | “30” | “0” | “7” | “8” | “8” | “0” | “16” | “1” |
| Chemotherapy within 8 weeks (yes/no; therapy) | “Y; LuTate” | “Y; FOLFOX” | “Y; Pembrolizumab” | “Y; CAPTEM” | “Y; LuTate” | “NA” | “Y; FOLFOX” | “Y; CAPTEM” |
| Surgery within 8 weeks (yes/no; procedure) | “N” | “Y; Whipple Surgery and Left Hepatectomy” | “Y; Total hysterectomy and bilateral oophorectomy” | “Y; Partial Pancreatectomy” | “N” | “N” | “N” | “Y; Hemi-hepatectomy” |
| Other medical procedure within 8 weeks (yes/no; type) | “N” | “Y; HACE” | “N” | “Y; HAE” | “Y; HAE” | “Y; HAE” | “Y; HAE” | “NA” |
| ECOG at 3 months | “0” | “2” | “0” | “0” | “0” | “0” | “1” | “0” |
| Overall survival | “14 months” | “5 months” | “5 months” | “14 months” | “17 months (living)” | “14 months (living)” | “6 months” | “10 months” |
| Cause of death | “Tumor progression” | “Tumor progression” | “Tumor progression” | “Tumor progression” | “NA” | “NA” | “MDS Progression/Sepsis” | “Tumor Progression” |

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-6"></a>

##### Time below 70 mg/dL, time below 54 mg/dL, and hyperglycemia by continuous glucose monitoring

> “Seven of 8 individuals achieved a reduction in percent time in hypoglycemia, with a mean decrease from 12.4% at baseline to 8.0% after receiving ersodetug (35.6% relative reduction), equating to a median absolute change of −3.8% (90% CI, −8.2 to −1.1; P = .02)”
> “Percent time in Level 2 hypoglycemia (<54 mg/dL) also trended numerically lower, with a mean decrease from 2.6% at baseline to 1.9% after receiving ersodetug (median absolute change of −0.5%; 90% CI, −2.9 to 1.3; P = .38).”
> “Reductions in overnight percent time in overall and Level 2 hypoglycemia were also observed, but statistical evidence was limited.”
> “No hyperglycemia-related adverse events or need for insulin were reported.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-7"></a>

##### Continuous glucose monitoring parameters over 24 hours, by day, and by night

| Period and parameter | Baseline, 90 days before initiation: mean (min, max) | Evaluable period, 90 days after initiation: mean (min, max) | Relative change from baseline (%) | Median change from baseline (90% CI) | P value |
| --- | --- | --- | --- | --- | --- |
| 24 hours: mean sensor glucose (mg/dL) | “117.0 (86.9, 157.6)” | “138.0 (94.3, 189.5)” | “18.0” | “21.6 (6.5, 36.1)” | “0.02” |
| 24 hours: time above 180 (%) | “10.1 (0.6, 29.3)” | “22.7 (0.2, 56.1)” | “124.4” | “13.5 (2.9, 24.3)” | “0.02” |
| 24 hours: time between 70 and 180 (%) | “77.4 (61.0, 95.0)” | “69.2 (43.9, 87.3)” | “−10.6” | “−8.2 (−20.2, 4.8)” | “0.08” |
| 24 hours: time below 70 (%) | “12.4 (1.7, 25.9)” | “8.0 (0.0, 22.4)” | “−35.6” | “−3.8 (−8.2, −1.1)” | “0.02” |
| 24 hours: time below 54 (%) | “2.6 (0.0, 5.2)” | “1.9 (0.0, 6.8)” | “−29.2” | “−0.5 (−2.9, 1.3)” | “0.38” |
| Day (06:00 to 00:00): mean sensor glucose (mg/dL) | “117.2 (86.9, 155.7)” | “139.5 (99.0, 191.2)” | “19.0” | “21.8 (9.5, 36.9)” | “0.008” |
| Day: time above 180 (%) | “10.4 (0.7, 31.7)” | “23.2 (0.3, 57.7)” | “123.0” | “12.9 (3.8, 23.7)” | “0.02” |
| Day: time between 70 and 180 (%) | “76.8 (58.2, 95.0)” | “69.4 (42.3, 92.6)” | “−9.6” | “−6.2 (−19.7, 7.4)” | “0.25” |
| Day: time below 70 (%) | “12.8 (0.8, 27.5)” | “7.3 (0.0, 22.3)” | “−42.6” | “−4.6 (−11.6, −0.7)” | “0.02” |
| Day: time below 54 (%) | “2.7 (0.0, 4.5)” | “2.0 (0.0, 7.2)” | “−26.8” | “−0.7 (−2.8, 1.4)” | “0.46” |
| Night (00:00 to 06:00): mean sensor glucose (mg/dL) | “116.4 (87.0, 163.3)” | “134.2 (80.3, 196.6)” | “15.2” | “15.6 (−3.1, 43.2)” | “0.11” |
| Night: time above 180 (%) | “9.3 (0.0, 26.4)” | “21.6 (0.0, 57.4)” | “132.1” | “9.3 (0.6, 26.7)” | “0.02” |
| Night: time between 70 and 180 (%) | “79.3 (69.4, 95.0)” | “68.3 (42.0, 90.8)” | “−13.9” | “−7.5 (−23.9, −1.0)” | “0.02” |
| Night: time below 70 (%) | “11.3 (0.8, 26.0)” | “10.0 (0.0, 28.8)” | “−11.8” | “−1.1 (−4.5, 2.6)” | “0.25” |
| Night: time below 54 (%) | “2.5 (0.0, 7.6)” | “1.6 (0.0, 5.4)” | “−37.1” | “−1.1 (−4.8, 2.4)” | “0.55” |

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-8"></a>

##### Continuous glucose monitoring sensitivity analysis

> “In a sensitivity analysis that incorporated all available CGM data beyond the initial 90-day windows for patients with evaluable recordings, clinical patterns remained consistent with the primary analysis”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-9"></a>

##### Hospital discharge and tumor-directed therapy after initiation

> “The median time to hospital discharge after initiation of ersodetug was 9 days (range, 1-84); all patients hospitalized at baseline (n = 6) were discharged to home for treatment, including 2 who were previously considering hospice-level care.”
> “Within 8 weeks of ersodetug initiation, nearly all individuals (n = 7) were able to proceed with tumor-directed therapies, including chemotherapy (n = 7), surgery (n = 4), and other medical procedures such as hepatic arterial embolization (n = 5).”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-10"></a>

##### Performance status at 3 months

> “ECOG performance status was evaluated 3 months after initial ersodetug administration; 6 individuals had a score of 0, 4 of whom improved from a baseline score of 3.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-11"></a>

##### Response by starting dose

> “Glycemic stabilization was achieved across dosing regimens, with a more pronounced response observed in individuals initiated at 9 mg/kg weekly.”
> “More protracted responses to ersodetug and longer times to hospital discharge in initially treated individuals were associated with lower starting doses and less frequent administration of ersodetug (6 mg/kg and/or biweekly administration).”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.3-12"></a>

##### ENDO 2026 poster: 7 of 8 patients on parenteral glucose with at least 50% reduction

> “Seven of the 8 patients receiving parenteral glucose at baseline achieved at least a 50% reduction (‘responder’; highlighted in table above)”
> “associated with marked to complete reduction in parenteral glucose dependence and enhanced functional status”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-3.1.2.8.3-13"></a>

##### Glucose infusion rate, hospitalization, and performance status outcomes by patient in the company table of 9 patients

| Outcome | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Percent reduction in GIR by 8 weeks | “>50%, then 100% by 9 weeks” | “<50%” | “100%” | “100%” | “100%” | “n/a” | “100%” | “Unknown amount” | “100%” |
| Time to IV glucose discontinuation (days) | “74” | “139 (achieved 50% reduction)” | “4” | “5” | “2” | “n/a” | “3” | “n/a” | “42” |
| Hospitalized days in the 30 days after initiation | “30” | “0” | “7” | “8” | “8” | “0” | “16” | “30” | “1” |
| ECOG at month 3 | “0” | “2” | “0” | “0” | “0” | “0” | “1” | “5” | “0” |

Source: [Rezolute EAP patient profiles (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-2.htm)

<a id="topic-3.1.2.8.3-14"></a>

##### Company summary: 75% of patients on IV dextrose or parenteral nutrition discontinued it

> “In summary, 75% of the patients receiving IV dextrose/total parenteral nutrition (TPN) in the EAP achieved a complete discontinuation of IV dextrose/TPN.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

> “Complete discontinuation of IV dextrose/total parenteral nutrition (TPN) in 75% of patients”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-3.1.2.8.3-15"></a>

##### NANETS 2024 poster: 4 of 5 patients discontinued parenteral dextrose

> “Four  patients achieved complete discontinuation, and one achieved a 50% reduction in intravenous carbohydrate support after dose increase to 9mg/kg.”
> “Three patients achieved complete resolution of hypoglycemia within two weeks of starting treatment.”
> “More protracted responses occurred in patients who initially received ersodetug at a lower dose or frequency.”

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-3.1.2.8.3-16"></a>

##### Single published case: hypoglycemia, dextrose infusion, and discharge after ersodetug

> “After the second RZ358 infusion (at a dose of 6 mg per kilogram of body weight), the hypoglycemia attenuated, with less than 1% of all sensor glucose values in each 24-hour period being less than 54 mg per deciliter, a result that permitted a reduction in the rate of dextrose infusion.”
> “After four additional infusions of RZ358 (each at a dose of 9 mg per kilogram), metabolic stability allowed discontinuation of other therapies, despite persistent excessive insulin secretion, elevated lactate dehydrogenase level”
> “Initiation of the anti–insulin receptor monoclonal antibody RZ358 (day 0) was successful in reducing the frequency of hypoglycemia, and the patient was able to safely receive a second dose of LU (day 67), which allowed for discharge home on day 83 after initiation of RZ358 therapy.”
> “The patient has remained free of severe hypoglycemia after 9 months of RZ358 therapy, currently administered at monthly intervals, with no evidence of adverse effects.”

Source: [Osataphan et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10506502/)

<a id="topic-3.1.2.8.3-17"></a>

##### Second patient: insulin-secreting cervical cancer

> “The patient began receiving treatment with RZ358 in September 2023, which resulted in resolution of her hypoglycemia and enabled her to be discharged from the hospital to resume cancer-directed therapy while continuing to receive RZ358 to control hypoglycemia.”

Source: [Rezolute tumor HI evidence release (2023)](https://ir.rezolutebio.com/news/detail/318/rezolute-announces-further-evidence-of-rz358s-efficacy-in-tumor-mediated-hyperinsulinism)

Additional sources: [Schubert et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37888935/); [Osataphan et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37888936/)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

##### No quality of life instrument: functional benefit reported as clinician-rated performance status

> “With improvements in glycemic control, all individuals experienced associated functional benefits, including hospital discharge in previously prolonged inpatient cases, and marked improvements in ECOG performance status.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.4-2"></a>

##### Resumption of daily activities, as stated by the company without a measurement instrument

> “Ability to resume regular daily activities (e.g., driving)”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

> “Ability to resume normal activities (e.g., walking, driving, traveling)”

Source: [Rezolute investor event presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm)

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Serious adverse events and drug-related events in the peer-reviewed case series

> “No drug-related serious adverse events were observed.”
> “Ersodetug was generally safe and well tolerated among all individuals and across all dose levels and regimens.”
> “There were no drug-related deaths, adverse drug reactions, discontinuations due to adverse events, treatment-emergent clinically significant laboratory abnormalities indicative of organ toxicity, or other dose-limiting toxicities, as determined by treating physicians and reviewed by the sponsor's safety committee.”
> “As depicted in Table 4, 3 of 8 individuals experienced serious adverse events, all attributed to underlying tumor progression or tumor-directed therapies.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.5-2"></a>

##### Treatment-emergent serious adverse events, pooled cohort of 8

| Measure | Pooled cohort (n = 8), number (%) |
| --- | --- |
| Individuals with serious TEAEs, n (%) | “3 (37.5%)” |
| Total SAEs | “4” |
| Individuals with PI-judged study drug-related SAEs, n (%) | “0 (0%)” |
| Grade 1 (mild) | “1 (12.5%)” |
| Grade 2 (moderate) | “0 (0%)” |
| Grade 3 (severe) | “2 (25%)” |
| Grade 4 (life-threatening) | “1 (12.5%)” |
| Grade 5 (death) | “0 (0%)” |

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.5-3"></a>

##### Disease progression not counted as an adverse event, and hyperglycemia

> “Disease progression was not reported as a treatment-emergent adverse event, as per EAP treatment guidelines.”
> “A corresponding increase in time above 180 mg/dL was observed, but without associated clinical impact.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-3.1.2.8.5-4"></a>

##### ENDO 2026 poster: no drug-related serious adverse events in 9 patients

> “All patients tolerated ersodetug with no drug-related serious adverse events”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-3.1.2.8.5-5"></a>

##### NANETS 2024 poster: tolerability in 5 patients

> “Ersodetug was generally safe and well-tolerated, and patients were able to stop or substantially reduce parenteral dextrose, enabling hospital discharge after initiating therapy.”

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-3.1.2.8.5-6"></a>

##### Company statement on side effects

> “Substantial hypoglycemia improvement with no significant side effects”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

- Design: the peer-reviewed report is a retrospective case series of 8 individuals treated under single-patient compassionate use, with no control group. The authors used nominal P-values without formal or prespecified hypothesis testing, could not construct 95% intervals, and developed the statistical analysis plan after the primary analyses.
- Confounding: within 8 weeks of starting ersodetug, 7 individuals received chemotherapy, 4 had surgery, and 5 had other procedures such as hepatic arterial embolization, which can also reduce hypoglycemia. Doses and schedules changed during the program, and the first 2 individuals were treated under an earlier framework at a lower weekly dose.
- Inconsistent counts and data: the number of patients differs by source (5 in the NANETS 2024 poster, 8 in the publication, 9 in the company table and ENDO 2026 poster). The company table and the publication differ in a patient's sex (“F; 74” and “M / 74”), and the publication gives hospitalization at entry as “median, 28 days; range, 4-66 days” in its text while its table lists a longest stay of 49 days. A company release describes the 9 patients as having malignant insulinoma and non-islet cell tumors, while the case-level tables list insulin-secreting tumors.
- Overlap: the first patient's glucose data were previously published as a single case report, so that case is not independent evidence.
- Safety ascertainment: disease progression was not reported as an adverse event under the program guidelines.

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/); [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf); [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf); [Rezolute EAP patient profiles (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-2.htm); [Rezolute ENDO presentations release (2026)](https://ir.rezolutebio.com/news/detail/380/rezolute-highlights-results-presented-from-natural-history-outcomes-studies-and-its-ersodetug-clinical-program-in-hyperinsulinism-at-annual-meeting-of-the-endocrine-society)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
